Page 7 - Topline News Today

LPCN 1154 Oral Neuroactive Steroid for Depression Disorders Topline Results PK Bridge Clinical... | May 17, 2023

45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-ADTM response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on

*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023

ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive... | May 16, 2023

Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif.,... | May 11, 2023

Topline data are expected in second half of 2023. EMBARK will be the first completed randomized study of an IBAT inhibitor for the treatment of biliary atresia. ... | May 11, 2023

Phase 2 trials of VTX958 are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 in... | May 11, 2023

Core business outperforms, delivering 14% topline growth; Customer acquisition strength in March drives full-year guidance higher; Unlevered free cash flow margin of 28% resulting from pricing... | May 9, 2023

WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday positive Phase 2 topline results for COVID-Influenza Combination, standalone influenza, and high-dose COVID vaccine candidates.These

Press Release: Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6 - OMN6 demonstrates safety and tolerability at clinically significant